Cara Therapeutics (NASDAQ:CARA) had its target price increased by stock analysts at Cantor Fitzgerald from $29.00 to $33.00 in a report released on Wednesday, The Fly reports. Cantor Fitzgerald’s price target indicates a potential upside of 92.98% from the stock’s current price.
CARA has been the topic of several other research reports. BidaskClub raised Cara Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Wednesday. HC Wainwright reiterated a “buy” rating and issued a $30.00 target price on shares of Cara Therapeutics in a research note on Tuesday. Needham & Company LLC restated a “buy” rating and issued a $35.00 price objective on shares of Cara Therapeutics in a research report on Tuesday. Zacks Investment Research cut Cara Therapeutics from a “hold” rating to a “sell” rating in a research note on Tuesday, October 8th. Finally, ValuEngine upgraded shares of Cara Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Tuesday. One research analyst has rated the stock with a sell rating, one has given a hold rating, seven have given a buy rating and two have given a strong buy rating to the stock. Cara Therapeutics has an average rating of “Buy” and an average price target of $27.54.
Shares of CARA stock traded up $0.16 on Wednesday, reaching $17.10. 138,564 shares of the company’s stock traded hands, compared to its average volume of 472,985. The company has a debt-to-equity ratio of 0.02, a quick ratio of 4.21 and a current ratio of 4.21. Cara Therapeutics has a 12-month low of $12.19 and a 12-month high of $27.55. The business’s 50 day moving average price is $21.49 and its two-hundred day moving average price is $21.62. The company has a market capitalization of $1.04 billion, a P/E ratio of -8.29 and a beta of 2.30.
Cara Therapeutics (NASDAQ:CARA) last issued its quarterly earnings data on Tuesday, November 5th. The biopharmaceutical company reported ($0.74) earnings per share for the quarter, missing the consensus estimate of ($0.59) by ($0.15). Cara Therapeutics had a negative net margin of 470.70% and a negative return on equity of 70.35%. The business had revenue of $5.79 million for the quarter, compared to the consensus estimate of $5.56 million. Research analysts predict that Cara Therapeutics will post -2.55 earnings per share for the current year.
In other Cara Therapeutics news, Director Jeffrey L. Ives sold 2,500 shares of the business’s stock in a transaction dated Friday, November 1st. The stock was sold at an average price of $20.68, for a total transaction of $51,700.00. Following the completion of the sale, the director now directly owns 8,500 shares in the company, valued at approximately $175,780. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, CEO Derek T. Chalmers sold 10,000 shares of the business’s stock in a transaction on Tuesday, October 1st. The shares were sold at an average price of $18.28, for a total transaction of $182,800.00. Following the sale, the chief executive officer now directly owns 933,468 shares of the company’s stock, valued at approximately $17,063,795.04. The disclosure for this sale can be found here. Over the last three months, insiders have sold 36,000 shares of company stock worth $692,495. Insiders own 5.80% of the company’s stock.
Several institutional investors have recently added to or reduced their stakes in CARA. Aperio Group LLC bought a new stake in shares of Cara Therapeutics in the 2nd quarter worth about $88,000. Russell Investments Group Ltd. purchased a new stake in shares of Cara Therapeutics in the third quarter valued at approximately $110,000. Penserra Capital Management LLC purchased a new position in shares of Cara Therapeutics during the third quarter valued at $180,000. Squarepoint Ops LLC bought a new position in shares of Cara Therapeutics during the third quarter valued at approximately $190,000. Finally, Sfmg LLC bought a new stake in Cara Therapeutics during the 2nd quarter valued at $200,000. Hedge funds and other institutional investors own 76.08% of the company’s stock.
Cara Therapeutics Company Profile
Cara Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and immune cells.
Featured Article: FAANG Stocks
Receive News & Ratings for Cara Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cara Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.